FDA Approved: AMBRISENTAN — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

FDA approved Cipla USA Inc.'s supplemental application for ambrisentan (ANDA 210715).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)